How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

112,660 results for

Treating Family Members

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. "She Had a Smile on Her Face as Wide as the Great Australian Bite": A Qualitative Examination of Family Perceptions of a Therapeutic Robot and a Plush Toy. (PubMed)

"She Had a Smile on Her Face as Wide as the Great Australian Bite": A Qualitative Examination of Family Perceptions of a Therapeutic Robot and a Plush Toy. Recent years have seen social robotic pets introduced as a means of treating behavioral and psychological symptoms of dementia, and many show promising potential. In this study, we sought to explore family members' perceptions of the Japanese-developed baby harp seal, Paro (version 9), and a look-alike, nonrobotic Plush Toy, when used (...) by their relative with dementia for 15 min, 3 afternoons per week for 10 weeks.The study employed a descriptive qualitative approach, which was nested within a larger cluster randomized controlled trial. A convenience sample of 20 family members (n = 10 each from the Paro and Plush Toy conditions) with relatives in 9 long-term care facilities in Queensland, Australia, completed individual semi-structured interviews (telephone or face-to-face). Inductive, data-driven thematic analysis of the data was undertaken

Full Text available with Trip Pro

2019 The Gerontologist

142. Novel SCN2A mutation in a family associated with juvenile-onset myoclonus: Case report. (PubMed)

Novel SCN2A mutation in a family associated with juvenile-onset myoclonus: Case report. The phenotypic spectrum caused by SCN2A mutations includes benign neonatal/infantile seizures, Ohtahara syndrome, infantile spasms, West syndrome, and other unclassified epileptic phenotypes. Mutations in SCN2A have been implicated in neonatal seizure cases. Here, we described a Chinese family with 2 members having juvenile-onset myoclonus and identified a novel SCN2A point mutation within this family.The 21 (...) analyses.Genetic testing revealed a novel SCN2A variant, c.T4820C, which contains a highly conserved amino acid substitution within segment S5 (p.V1607A). This mutation was predicted to produce a dysfunctional Nav1.2 protein by Mutation Taster and Protein Variation Effect Analyzer (PROVEAN). Genotype-phenotype correlation showed an incomplete penetrance of p.V1607A.The proband was treated by multiple antiepileptic drugs. These included carbamazepine, oxcarbazepine, valproate, and topiramate.The duration

2019 Medicine

143. A transient DMSO treatment increases the differentiation potential of human pluripotent stem cells through the Rb family. (PubMed)

, we demonstrated that pre-treating hPSCs with dimethylsulfoxide (DMSO) before directed differentiation enhanced differentiation potential across all three germ layers. Here, we show that exposure to DMSO improves the efficiency of hPSC differentiation through Rb and by repressing downstream E2F-target genes. While transient inactivation of the Rb family members (including Rb, p107, and p130) suppresses DMSO's capacity to enhance differentiation across all germ layers, transient expression (...) A transient DMSO treatment increases the differentiation potential of human pluripotent stem cells through the Rb family. The propensity for differentiation varies substantially across human pluripotent stem cell (hPSC) lines, greatly restricting the use of hPSCs for cell replacement therapy or disease modeling. Here, we investigate the underlying mechanisms and demonstrate that activation of the retinoblastoma (Rb) pathway in a transient manner is important for differentiation. In prior work

Full Text available with Trip Pro

2018 PLoS ONE

144. Assessing health impacts of home food gardens with Wind River Indian Reservation families: protocol for a randomised controlled trial. (PubMed)

after 2 years of data collection). Willing family members aged 5 and up will participate in data collection each February and August for 2 years, with blood, biometric and survey measures at each. The primary outcome is adult body mass index (BMI). Secondary outcomes include child BMI, and adult hand strength, self-reported physical and mental health, diabetes control and food security. Primary analysis will be intention to treat (ITT), using univariate and bivariate descriptive statistics followed (...) Assessing health impacts of home food gardens with Wind River Indian Reservation families: protocol for a randomised controlled trial. This community-based participatory research, Growing Resilience, will be the first full-scale randomised controlled trial we have identified that is designed to evaluate impacts of home gardening on family health. It is based on observational studies suggesting home food gardening has myriad health benefits, Wind River Indian Reservation (WRIR) families

Full Text available with Trip Pro

2019 BMJ open

145. Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure. (PubMed)

Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure. Concentrations of soluble (s)ST2 predict prognosis in heart failure. We recently found changing doses of β-blocker (BB) may affect sST2 concentrations. It remains unclear whether sST2 concentrations identify benefit of BB therapy, however.A total of 151 subjects with heart failure attributable to left ventricular systolic dysfunction were examined in this post hoc analysis; >96 (...) sST2/high-dose BB had intermediate outcomes (0.92 and 1.19 events). Patients with high sST2 treated with low-dose BB had the highest cardiovascular event rate (2.08 events) and the highest cumulative hazard. Compared with low sST2/high-dose BB, those with high sST2 treated with low-dose BB had an odds ratio of 6.77 (P<0.001) for a cardiovascular event. Patients with low sST2/low-dose BB or high sST2/high-dose BB had intermediate odds ratios for cardiovascular events (P=0.18 and 0.02). Similar

Full Text available with Trip Pro

2013 Circulation. Heart failure

146. Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure. (PubMed)

Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure. Concentrations of soluble (s)ST2 predict prognosis in heart failure. We recently found changing doses of β-blocker (BB) may affect sST2 concentrations. It remains unclear whether sST2 concentrations identify benefit of BB therapy, however.A total of 151 subjects with heart failure attributable to left ventricular systolic dysfunction were examined in this post hoc analysis; >96 (...) sST2/high-dose BB had intermediate outcomes (0.92 and 1.19 events). Patients with high sST2 treated with low-dose BB had the highest cardiovascular event rate (2.08 events) and the highest cumulative hazard. Compared with low sST2/high-dose BB, those with high sST2 treated with low-dose BB had an odds ratio of 6.77 (P<0.001) for a cardiovascular event. Patients with low sST2/low-dose BB or high sST2/high-dose BB had intermediate odds ratios for cardiovascular events (P=0.18 and 0.02). Similar

Full Text available with Trip Pro

2013 Circulation. Heart failure

147. Oncogenetic testing, diagnosis and follow-up in Birt-Hogg-Dubé syndrome, familial atypical multiple mole melanoma syndrome and neurofibromatosis 1 and 2

, Poppe B. Oncogenetic testing, diagnosis and follow-up in Birt-Hogg-Dubé syndrome, familial atypical multiple mole melanoma syndrome and neurofibromatosis 1 and 2. Brussels: Belgian Health Care Knowledge Centre (KCE). KCE Reports 243. 2015 Authors' objectives This guideline treats the Birt-Hogg-Dubé syndrome, the familial atypical multiple mole melanoma syndrome and neurofibromatosis 1&2. These syndromes only have in common that dermatological manifestations are involved, but implications, risks (...) Oncogenetic testing, diagnosis and follow-up in Birt-Hogg-Dubé syndrome, familial atypical multiple mole melanoma syndrome and neurofibromatosis 1 and 2 Oncogenetic testing, diagnosis and follow-up in Birt-Hogg-Dubé syndrome, familial atypical multiple mole melanoma syndrome and neurofibromatosis 1 and 2. Oncogenetic testing, diagnosis and follow-up in Birt-Hogg-Dubé syndrome, familial atypical multiple mole melanoma syndrome and neurofibromatosis 1 and 2. Robays J, Stordeur S, Hulstaert F

2015 Health Technology Assessment (HTA) Database.

148. Eliglustat for treating type 1 Gaucher disease

project team 43 Evaluation committee members 43 NICE project team 43 Eliglustat for treating type 1 Gaucher disease (HST5) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 441 1 Recommendations Recommendations 1.1 Eliglustat is recommended within its marketing authorisation for treating type 1 Gaucher disease, that is, for long-term treatment in adults who are cytochrome P450 2D6 poor, intermediate or extensive (...) Eliglustat for treating type 1 Gaucher disease Eliglustat for treating type 1 Gaucher Eliglustat for treating type 1 Gaucher disease disease Highly specialised technologies guidance Published: 28 June 2017 nice.org.uk/guidance/hst5 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful

2017 National Institute for Health and Clinical Excellence - Highly specialised technology

149. Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia

committee members 21 NICE project team 21 Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 221 1 Recommendations Recommendations 1.1 Blinatumomab is recommended within its marketing authorisation as an option for treating Philadelphia-chromosome-negative relapsed or refractory precursor B-cell acute (...) Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia Blinatumomab for pre Blinatumomab for previously treated viously treated Philadelphia-chromosome-negativ Philadelphia-chromosome-negative e acute lymphoblastic leukaemia acute lymphoblastic leukaemia T echnology appraisal guidance Published: 28 June 2017 nice.org.uk/guidance/ta450 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

150. Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia

guidance 241) 19 Cancer Drugs Fund partial reconsideration of NICE technology appraisal guidance 241 19 Summary of appraisal committee's key conclusions 21 5 Implementation 31 6 Appraisal committee members and NICE project team 32 Appraisal committee members 32 NICE project team 32 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms (...) Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia Dasatinib, nilotinib and high-dose Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or imatinib for treating imatinib-resistant or intoler intolerant chronic m ant chronic my yeloid leukaemia eloid leukaemia T echnology appraisal guidance Published: 21 December 2016 nice.org.uk/guidance/ta425 © NICE 2018. All rights reserved. Subject to Notice of rights

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

151. Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens

members and NICE project team 24 Appraisal committee members 24 NICE project team 24 Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 25This guidance replaces TA250. This guidance should be read in conjunction with TA515. 1 1 Recommendations Recommendations 1.1 Eribulin is recommended as an option (...) with locally advanced or metastatic breast cancer, whose disease has progressed after at least 2 chemotherapy regimens. The committee concluded that eribulin is particularly valuable, and has been more widely used, for HER2-negative disease because this has fewer treatment options. It also recognised that the availability of additional treatment options for advanced disease would be valued by patients and their families. 4.1 to 4.3 The technology The technology Eribulin for treating locally advanced

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

152. Cladribine tablets for treating relapsing?remitting multiple sclerosis

-effectiveness results and conclusion 18 4 Implementation 20 5 Appraisal committee members and NICE project team 21 Appraisal committee members 21 NICE project team 21 Cladribine tablets for treating relapsing–remitting multiple sclerosis (TA493) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 221 1 Recommendations Recommendations 1.1 Cladribine tablets are recommended as an option for treating highly active multiple (...) Cladribine tablets for treating relapsing?remitting multiple sclerosis Cladribine tablets for treating Cladribine tablets for treating relapsing–remitting multiple sclerosis relapsing–remitting multiple sclerosis T echnology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta493 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

153. Ibrutinib for treating Waldenstrom?s macroglobulinaemia

discussion 7 Clinical effectiveness 7 Cost effectiveness 11 Potential equality issues 15 Pharmaceutical Price Regulation Scheme (PPRS) 2014 15 Summary of appraisal committee's key conclusions 16 5 Implementation 22 6 Recommendation for data collection 23 7 Appraisal committee members and NICE project team 24 Appraisal committee members 24 NICE project team 24 Ibrutinib for treating Waldenstrom’s macroglobulinaemia (TA491) © NICE 2018. All rights reserved. Subject to Notice of rights (https (...) Ibrutinib for treating Waldenstrom?s macroglobulinaemia Ibrutinib for treating W Ibrutinib for treating Waldenstrom aldenstrom’s ’s macroglobulinaemia macroglobulinaemia T echnology appraisal guidance Published: 22 November 2017 nice.org.uk/guidance/ta491 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

154. Venetoclax for treating chronic lymphocytic leukaemia

Symptoms and management of CLL 7 Clinical effectiveness 9 Indirect comparison with best supportive care 12 Cost effectiveness 13 Cancer Drugs Fund considerations 20 Summary of appraisal committee's key conclusions 22 5 Implementation 30 6 Recommendations for data collection 31 7 Appraisal committee members and NICE project team 32 Appraisal committee members 32 NICE project team 32 Venetoclax for treating chronic lymphocytic leukaemia (TA487) © NICE 2018. All rights reserved. Subject to Notice (...) Venetoclax for treating chronic lymphocytic leukaemia V Venetoclax for treating chronic enetoclax for treating chronic lymphocytic leukaemia lymphocytic leukaemia T echnology appraisal guidance Published: 8 November 2017 nice.org.uk/guidance/ta487 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived at after

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

155. Nivolumab for previously treated non-squamous non-small-cell lung cancer

Recommendations 4 2 The technology 5 3 Evidence 6 4 Committee discussion 7 Nature of the condition 7 Clinical management of the condition 7 Comparators 8 Clinical effectiveness 8 Cost effectiveness 11 End-of-life considerations 20 Innovation 21 Cancer Drugs Fund 21 Overall conclusions 24 Summary of appraisal committee's key conclusions 25 5 Implementation 32 6 Appraisal committee members and NICE project team 33 Appraisal committee members 33 NICE project team 33 Nivolumab for previously treated non-squamous (...) Nivolumab for previously treated non-squamous non-small-cell lung cancer Niv Nivolumab for pre olumab for previously treated non- viously treated non- squamous non-small-cell lung cancer squamous non-small-cell lung cancer T echnology appraisal guidance Published: 1 November 2017 nice.org.uk/guidance/ta484 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

156. Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours

Implementation 16 5 Appraisal committee members and NICE project team 17 Appraisal committee members 17 NICE project team 17 Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 181 1 Recommendations Recommendations 1.1 Regorafenib is recommended as an option for treating unresectable or metastatic gastrointestinal stromal (...) and that these are managed on an individual basis to achieve a balance between the minimal effective dose and side effects that can be tolerated. The patient experts explained that regorafenib allows people to Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 7 of 18remain actively engaged in work and family life, while reducing anxiety

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

157. “Treat me with respect”. What happens before, during and after coercion?

Treat me with respect”. What happens before, during and after coercion? “Treat me with respect”. What happens before, during & after coercion? Search National Elf Service Search National Elf Service » » » » » “Treat me with respect”. What happens before, during and after coercion? Nov 17 2017 Posted by Incidents involving violence and aggression are a frequent occurrence in adult mental health inpatient settings. They are managed by use of restrictive interventions (coercive practices (...) the therapeutic relationship between the patient and staff. Physical discomfort This included the effects and side effects of medication, as well as the physical and psychological effects of restraint, or seclusion. Other consequences The published literature suggested that longer term psychological outcomes resulted in subsequent trauma and potential delays to recovery. Psychiatric patients associate the use of coercive interventions with strong negative perceptions and wish to be treated with respect

2017 The Mental Elf

158. Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane

committee members and NICE project team 30 Appraisal committee members 30 NICE project team 30 Update information 32 Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 32This guidance replaces TA371. 1 1 Recommendations Recommendations 1.1 Trastuzumab emtansine is recommended, within its marketing (...) Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane T T r rastuzumab emtansine for treating astuzumab emtansine for treating HER2-positiv HER2-positive advanced breast cancer e advanced breast cancer after tr after trastuzumab and a taxane astuzumab and a taxane T echnology appraisal guidance Published: 19 July 2017 nice.org.uk/guidance/ta458 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

159. Adalimumab and dexamethasone for treating non-infectious uveitis

Evidence 7 4 Committee discussion 8 Clinical need and management of non-infectious uveitis 8 Clinical effectiveness 9 Cost effectiveness 12 Summary of appraisal committee's key conclusions 19 5 Implementation 27 6 Appraisal committee members and NICE project team 28 Appraisal committee members 28 NICE project team 28 Adalimumab and dexamethasone for treating non-infectious uveitis (TA460) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice (...) Adalimumab and dexamethasone for treating non-infectious uveitis Adalimumab and de Adalimumab and dexamethasone for xamethasone for treating non-infectious uv treating non-infectious uveitis eitis T echnology appraisal guidance Published: 26 July 2017 nice.org.uk/guidance/ta460 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

160. Carfilzomib for previously treated multiple myeloma

problem and treatment pathway 8 Clinical effectiveness 11 Cost effectiveness 14 Most plausible incremental cost-effectiveness ratio 17 End-of-life considerations 19 Conclusion 19 Summary of appraisal committee's key conclusions 20 5 Implementation 27 6 Appraisal committee members and NICE project team 28 Appraisal committee members 28 NICE project team 28 Carfilzomib for previously treated multiple myeloma (TA457) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk (...) treated multiple myeloma (TA457) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 27 of 296 6 Appr Appraisal committee members and NICE project team aisal committee members and NICE project team Appraisal committee members The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any interests in the technology

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>